Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Obesity

Free Subscription Articles published in Lancet Retrieve available abstracts of 55 articles: HTML format

Single Articles

September 2025
1. THE LANCET
   Childhood obesity: a global health crisis.
   Lancet. 2025;406:1193.
   PubMed    
   
   
   
2. HUNTER KE, Nguyen D, Libesman S, Williams JG, et al
   Parent-focused behavioural interventions for the prevention of early childhood obesity (TOPCHILD): a systematic review and individual participant data meta-analysis.
   Lancet. 2025 Sep 10:S0140-6736(25)01144-4. doi: 10.1016/S0140-6736(25)01144.
   PubMed     Abstract available
   
   
   August 2025
3. ROBERT M, Poghosyan T, Romain-Scelle N, Czernichow S, et al
   Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-en-Y gastric bypass in France (SADISLEEVE): results of a randomised, open-label, superiority trial at 2 years of follow-up.
   Lancet. 2025;406:846-859.
   PubMed     Abstract available
   
   
   
4. ELLS LJ, Homer C, Matu J, Aswani D, et al
   Compassionate child obesity care within a stigmatising society.
   Lancet. 2025;406:444.
   PubMed    
   
   
   July 2025
5. DAHL K, Toubro S, Dey S, Duque do Vale R, et al
   Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
   Lancet. 2025;406:149-162.
   PubMed     Abstract available
   
   
   
6. GASIOREK A, Heydorn A, Gabery S, Hjerpsted JB, et al
   Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
   Lancet. 2025;406:135-148.
   PubMed     Abstract available
   
   
   June 2025
7. KHOO B, Tan TM
   GLP-1 and amylin receptor multiagonism with amycretin for obesity management.
   Lancet. 2025 Jun 20:S0140-6736(25)01250-4. doi: 10.1016/S0140-6736(25)01250.
   PubMed    
   
   
   
8. LUK A, Wild SH, Jones S, Anjana RM, et al
   Early-onset type 2 diabetes: the next major diabetes transition.
   Lancet. 2025 Jun 20:S0140-6736(25)00830-X. doi: 10.1016/S0140-6736(25)00830.
   PubMed     Abstract available
   
   
   February 2025
9. 
   Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
   Lancet. 2025 Feb 28:S0140-6736(25)00355-1. doi: 10.1016/S0140-6736(25)00355.
   PubMed     Abstract available
   
   
   
10. 
    Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
    Lancet. 2025 Feb 28:S0140-6736(25)00397-6. doi: 10.1016/S0140-6736(25)00397.
    PubMed     Abstract available
    
    
    
11. SORENSEN TIA
    Forecasting the global obesity epidemic through 2050.
    Lancet. 2025 Feb 28:S0140-6736(25)00260-0. doi: 10.1016/S0140-6736(25)00260.
    PubMed    
    
    
    January 2025
12. HORTON R
    Offline: Making obesity matter.
    Lancet. 2025;405:284.
    PubMed    
    
    
    
13. KLOPPENBURG M, Namane M, Cicuttini F
    Osteoarthritis.
    Lancet. 2025;405:71-85.
    PubMed     Abstract available
    
    
    November 2024
14. KIRBY T
    Brazil considers obesity discrimination law.
    Lancet. 2024;404:1912-1913.
    PubMed    
    
    
    
15. SEBERT S
    The obesity crisis in the USA: why are there no signs of plateauing yet?
    Lancet. 2024 Nov 12:S0140-6736(24)02467-X. doi: 10.1016/S0140-6736(24)02467.
    PubMed    
    
    
    
16. 
    National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.
    Lancet. 2024 Nov 12:S0140-6736(24)01548-4. doi: 10.1016/S0140-6736(24)01548.
    PubMed     Abstract available
    
    
    October 2024
17. EZZATI M, Zhou B, Bennett JE, Phelps NH, et al
    Assessing worldwide trends of underweight and obesity - Authors' reply.
    Lancet. 2024;404:1644.
    PubMed    
    
    
    
18. BOMBAK A, Riediger N
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1643.
    PubMed    
    
    
    
19. CHRISTENSEN DL, Bygbjerg IC
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1642.
    PubMed    
    
    
    
20. CZERNICHOW S, Ziegler O, Clement K, Coupaye M, et al
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1642-1643.
    PubMed    
    
    
    
21. VAN STEIJVOORT E, Borry P
    Assessing worldwide trends of underweight and obesity.
    Lancet. 2024;404:1641-1642.
    PubMed    
    
    
    August 2024
22. 
    General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
    Lancet. 2024;404:851-863.
    PubMed     Abstract available
    
    
    
23. NASIR K
    Embracing the duality of BMI and central adiposity.
    Lancet. 2024;404:824-825.
    PubMed    
    
    
    
24. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    PubMed     Abstract available
    
    
    
25. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    PubMed     Abstract available
    
    
    
26. LINGVAY I, Cohen RV, Roux CWL, Sumithran P, et al
    Obesity in adults.
    Lancet. 2024 Aug 16:S0140-6736(24)01210-8. doi: 10.1016/S0140-6736(24)01210.
    PubMed     Abstract available
    
    
    May 2024
27. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    PubMed    
    
    
    
28. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    PubMed     Abstract available
    
    
    April 2024
29. THE LANCET EDITORS
    Retraction and republication-Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2024;403:1321.
    PubMed    
    
    
    
30. SHI Q, Wang Y, Hao Q, Vandvik PO, et al
    Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2024;403:e21-e31.
    PubMed     Abstract available
    
    
    
31. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
    Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
    PubMed     Abstract available
    
    
    
32. DONAL E, L'Official G, Istratoaie S
    Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
    Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
    PubMed    
    
    
    March 2024
33. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    PubMed     Abstract available
    
    
    
34. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    PubMed    
    
    
    February 2024
35. TUMAS N, Lopez SR
    Double burden of underweight and obesity: insights from new global evidence.
    Lancet. 2024 Feb 29:S0140-6736(24)00051-5. doi: 10.1016/S0140-6736(24)00051.
    PubMed    
    
    
    
36. 
    Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
    Lancet. 2024 Feb 29:S0140-6736(23)02750-2. doi: 10.1016/S0140-6736(23)02750.
    PubMed     Abstract available
    
    
    
37. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
    Heart failure with preserved ejection fraction: everything the clinician needs to know.
    Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
    PubMed     Abstract available
    
    
    January 2024
38. THE LANCET
    Treating obesity and diabetes: drugs alone are not enough.
    Lancet. 2024;403:1.
    PubMed    
    
    
    December 2023
39. DANIELS JP
    Colombia introduces junk food tax.
    Lancet. 2023;402:2062.
    PubMed    
    
    
    November 2023
40. ZOU M, Northstone K, Leary S
    Causal effects of later-eating rhythm on adiposity in children through the comparison of two cohorts in the UK and China: a cross-cohort study.
    Lancet. 2023;402 Suppl 1:S99.
    PubMed     Abstract available
    
    
    
41. ALRUBAIAN F, Mulla Z
    Governments policy measures to address obesity among adults: a scoping review of the global evidence.
    Lancet. 2023;402 Suppl 1:S20.
    PubMed     Abstract available
    
    
    
42. CISNEROS AB, Headings R, Wells R, Reynolds C, et al
    Understanding the use of media analysis in public health research through food tax debates (HEALTHEI Project): a scoping review.
    Lancet. 2023;402 Suppl 1:S9.
    PubMed     Abstract available
    
    
    
43. SPAVIN A, Moore A, Lunn J, Tucker F, et al
    Reflecting on parental insights into healthy lifestyles: a qualitative study.
    Lancet. 2023;402 Suppl 1:S85.
    PubMed     Abstract available
    
    
    
44. CHEN S, Kuper H
    Tracing the temporal trends of modifiable risk factors in dementia: insights from the English Longitudinal Study of Ageing (2004-2019).
    Lancet. 2023;402 Suppl 1:S34.
    PubMed     Abstract available
    
    
    
45. WALSH S, Wallace L, Kuhn I, Mytton O, et al
    Population-level interventions for the primary prevention of dementia: a complex evidence review.
    Lancet. 2023;402 Suppl 1:S13.
    PubMed     Abstract available
    
    
    October 2023
46. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    PubMed    
    
    
    
47. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    PubMed     Abstract available
    
    
    September 2023
48. SUMITHRAN P, Finucane FM, Cohen RV
    Obesity drug shortages are symptomatic of wider malaise.
    Lancet. 2023 Sep 29:S0140-6736(23)01963-3. doi: 10.1016/S0140-6736(23)01963.
    PubMed    
    
    
    June 2023
49. GARVEY WT, Frias JP, Jastreboff AM, le Roux CW, et al
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi: 10.1016/S0140-6736(23)01200.
    PubMed     Abstract available
    
    
    
50. APOVIAN CM, McDonnell ME
    CagriSema and the link between obesity and type 2 diabetes.
    Lancet. 2023 Jun 23:S0140-6736(23)01291-6. doi: 10.1016/S0140-6736(23)01291.
    PubMed    
    
    
    
51. KNOP FK, Aroda VR, do Vale RD, Holst-Hansen T, et al
    Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01185-6. doi: 10.1016/S0140-6736(23)01185.
    PubMed     Abstract available
    
    
    
52. FALLOWS E, Ells L, Anand V
    Semaglutide and the future of obesity care in the UK.
    Lancet. 2023 Jun 5:S0140-6736(23)01083-8. doi: 10.1016/S0140-6736(23)01083.
    PubMed    
    
    
    May 2023
53. SKYLE D
    Fatima Cody Stanford: changing the narrative on obesity.
    Lancet. 2023;401:1644.
    PubMed    
    
    
    April 2023
54. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.
    PubMed    
    
    
    
55. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge.